Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,

Similar presentations


Presentation on theme: "Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,"— Presentation transcript:

1 Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3  Alexander Egeberg, MD, PhD, Jashin J. Wu, MD, Neil Korman, MD, PhD, James A. Solomon, MD, PhD, Orin Goldblum, MD, Fangyi Zhao, PhD, Lotus Mallbris, MD, PhD  Journal of the American Academy of Dermatology  Volume 79, Issue 1, Pages e8 (July 2018) DOI: /j.jaad Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Low-density lipoprotein (LDL)-to–high-density lipoprotein (HDL) ratio in the induction period (UNCOVER-1, UNCOVER-2, and UNCOVER-3; weeks 0-12) and maintenance period (UNCOVER-1 and UNCOVER-2; weeks 12-60; only placebo [PBO] and ixekizumab every 4 weeks [IXEQ4W]) when patients were treated with PBO, IXEQ4W, or ixekizumab every 2 weeks (IXEQ2W). Induction period results derived from the primary psoriasis placebo-controlled integrated analysis set, and maintenance period results derived from the psoriasis maintenance integrated analysis set. Journal of the American Academy of Dermatology  , e8DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

3 Supplemental Fig 1 Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3 were integrated into the primary psoriasis placebo-controlled integrated analysis set (weeks 0-12; UNCOVER-1, UNCOVER-2, and UNCOVER-3) (A), the primary psoriasis placebo- and active-controlled integrated analysis set (weeks 0-12; UNCOVER-2 and UNCOVER-3) (B), and the psoriasis maintenance integrated analysis set (weeks 12-60; UNCOVER-1 and UNCOVER-2) (C). ETN, Etanercept; IXEQ2W, ixekizumab every 2 weeks; IXEQ4W, ixekizumab every 4 weeks; PBO, placebo. Journal of the American Academy of Dermatology  , e8DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

4 Supplemental Fig 2 Low-density lipoprotein (LDL)-to–high-density lipoprotein (HDL) ratio in the ixekizumab integrated induction period for UNCOVER-2 and UNCOVER-3 (psoriasis placebo- and active-controlled integrated analysis set) when patients were treated with placebo (PBO), ixekizumab every 4 weeks (IXEQ4W), ixekizumab every 2 weeks (IXEQ2W), or etanercept (ETN) biweekly. Journal of the American Academy of Dermatology  , e8DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions


Download ppt "Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,"

Similar presentations


Ads by Google